依维莫司
医学
临床终点
肾细胞癌
内科学
中期分析
置信区间
无进展生存期
肿瘤科
泌尿科
临床试验
胃肠病学
外科
总体生存率
作者
Toni K. Choueiri,Thomas Powles,Katriina Peltola,Guillermo de Velasco,Mauricio Burotto,Cristina Suárez,Pooja Ghatalia,Roberto Iacovelli,Elaine T. Lam,Elena Verzoni,Mahmut Gümüş,Walter M. Stadler,Christian Kollmannsberger,Bohuslav Melichar,Balaji Venugopal,Marine Gross‐Goupil,Alexandr Poprach,Maria De Santis,Fabio A. Schutz,Se Hoon Park
标识
DOI：10.1056/nejmoa2313906
摘要
Belzutifan showed a significant benefit over everolimus with respect to progression-free survival and objective response in participants with advanced clear-cell renal-cell carcinoma who had previously received immune checkpoint and antiangiogenic therapies. Belzutifan was associated with no new safety signals. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; LITESPARK-005 ClinicalTrials.gov number, NCT04195750.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
不能玩一下午吗
宇宙无敌大火龙
zheei
Claudia
愔愔
BowieHuang
无极微光
寻道图强
tiptip
lc
qq
伯克利芙蓉王
Tttttttt
背后夜柳
独特奇异果
SciGPT
ff
271199
zzzz
皖公网安备34019202002308
